VF
ATXS

Virtu Financial’s Astria Therapeutics ATXS Stock Holding History

Virtu Financial’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,313
Closed -$427K – 1295
2024
Q1 		$427K Buy
+30,313
New +$378K 0.03% 466
2021
Q2 		– Sell
-5,855
Closed -$102K – 1498
2021
Q1 		$102K Sell
5,855
-8,015
-58% -$145K 0.01% 1316
2020
Q4 		$178K Buy
+13,870
New +$247K 0.02% 897
2019
Q2 		– Sell
-2,992
Closed -$142K – 1448
2019
Q1 		$142K Buy
+2,992
New +$101K 0.01% 1075
2018
Q3 		– Sell
-323
Closed -$19K – 1528
2018
Q2 		$19K Buy
+323
New +$29.8K ﹤0.01% 1864
2017
Q4 		– Sell
-2,207
Closed -$281K – 2350
2017
Q3 		$281K Buy
+2,207
New +$184K 0.01% 1454

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Virtu Financial's ATXS Position: Q2 2024 in Review

Virtu Financial sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 30,313 shares — an estimated $427K sold.

Virtu Financial first reported a position in ATXS in Q3 2017 and held it in 6 quarters. The position peaked at $427K in Q1 2024. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

  • Virtu Financial reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Virtu Financial sold 30,313 Astria Therapeutics shares in Q2 2024, an estimated $427K.
  • Virtu Financial first reported a position in Astria Therapeutics in Q3 2017 and held it in 6 quarters.
  • Virtu Financial's Astria Therapeutics position peaked at $427K in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on Virtu Financial's 13F filing for Q2 2024, filed 9 Aug 2024.